Last Posted: Jan 06, 2019
- https://www.cancer.gov/news-events/cancer-currents-blog/2019/early-stage-lung-cancer-biomarker
NCI, January 3, 2019 - Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Yi et al. Thoracic cancer 2018 Dec - Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment.
Lai Jinhuo et al. OncoTargets and therapy 2018 119111-9116 - Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples.
Pepe Francesco et al. Journal of clinical pathology 2019 Jan 72(1) 38-45 - Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.
Kehl Kenneth L et al. Journal of the National Cancer Institute 2018 Dec - Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer.
Ghiringhelli Francois et al. Oncotarget 2018 Nov 9(93) 36547-36548 - Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia J et al. Annals of oncology : official journal of the European Society for Medical Oncology 2018 Dec - Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
Linda Capková et al. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2018 31(5) 353-360 - Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
Udagawa Hibiki et al. Lung cancer (Amsterdam, Netherlands) 2018 Dec 126182-188 - Biomarkers in lung cancer screening: achievements, promises and challenges.
Seijo Luis M et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 Dec
.png)
No hay comentarios:
Publicar un comentario